Cadence Prevails Against Exela In Generic Ofirmev Row

Law360, Los Angeles (November 22, 2013, 8:11 PM EST) -- A Delaware federal judge has ruled against Exela Pharma Sciences LLC and its subsidiaries in favor of Cadence Pharmaceuticals Inc. in a patent infringement suit over plans to market a generic version of the injectable pain reliever Ofirmev, according to an opinion unsealed on Friday.

Cadence filed suit in 2011 alleging Exela had filed Abbreviated New Drug Applications seeking to make a generic version of Ofirmev, plans that also constituted infringement of U.S. Patent Numbers 6,028,222 and 6,992,218, which protect the branded pain reliever. On Nov....
To view the full article, register now.